MediciNova Posts Promising Data From COVID-19 Treatment Candidate

• MediciNova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed.

• The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure.

• The trial also achieved statistical significance for the proportion of subjects discharged from the hospital.

• Related: MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking.

• 71% of subjects in the MN-166 group and 35% of subjects in the placebo group were free of respiratory failure at Day 7.

• 71% of subjects in the MN-166 group and 47% of subjects in the placebo group had improved clinical status.

• 65% of subjects in the ibudilast group and 29% of subjects in the placebo group were discharged from the hospital.

• There were two deaths in the placebo group and no deaths in the MN-166 (ibudilast) group.

• There were no serious adverse events related to ibudilast.

• Price Action: MNOV shares are up 8.09% at $2.54 during the premarket session on the last check Wednesday.

See more from Benzinga

• EXCLUSIVE: Top 100 Insurer In Pact With SOBRsafe For Sponsored Customer Pilots

• Credit Suisse Warns On Q2 Loss, Mulls Workforce Reduction To Save Costs

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.